Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Recommendation of “Buy” from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have earned an average rating of “Buy” from the five research firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $8.80.

CARM has been the subject of a number of recent research reports. HC Wainwright cut their price objective on shares of Carisma Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. BTIG Research initiated coverage on shares of Carisma Therapeutics in a research note on Thursday, April 11th. They set a “buy” rating and a $6.00 target price on the stock.

Institutional Trading of Carisma Therapeutics

Hedge funds have recently bought and sold shares of the stock. CIBC Asset Management Inc purchased a new stake in Carisma Therapeutics in the 1st quarter worth $46,000. Tower Research Capital LLC TRC lifted its stake in Carisma Therapeutics by 534.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 10,982 shares of the company’s stock worth $46,000 after purchasing an additional 9,252 shares in the last quarter. Barclays PLC purchased a new stake in Carisma Therapeutics in the 2nd quarter worth $47,000. Deutsche Bank AG bought a new stake in shares of Carisma Therapeutics in the 3rd quarter worth about $52,000. Finally, SG Americas Securities LLC bought a new stake in shares of Carisma Therapeutics in the 3rd quarter worth about $58,000. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Trading Down 0.6 %

Shares of CARM stock opened at $1.69 on Thursday. Carisma Therapeutics has a 1 year low of $1.65 and a 1 year high of $9.77. The firm has a fifty day moving average price of $2.27 and a 200-day moving average price of $2.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.06 and a quick ratio of 5.06. The company has a market cap of $70.21 million, a price-to-earnings ratio of -0.49 and a beta of 0.95.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.